In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates

Citation
V. Coulon et al., In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates, INT J CANC, 88(5), 2000, pp. 783-790
Citations number
43
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF CANCER
ISSN journal
00207136 → ACNP
Volume
88
Issue
5
Year of publication
2000
Pages
783 - 790
Database
ISI
SICI code
0020-7136(200012)88:5<783:IVIOPT>2.0.ZU;2-3
Abstract
Presentation of cell-associated antigen to T cells is a critical event in t he initiation of an anti-tumor immune response but it appears to often be d eficient or limiting. Here we report an experimental system for stimulation of human T lymphocytes using autologous antigen presenting cells (APCs) an d autologous tumor cells. Two types of APCs were prepared from human bone m arrow: MC and DC. MC were produced by using GM-CSF and SCF. DC were obtaine d with the same cytokines plus IL-4. DC and MC were generated in parallel f rom the same patients and their phenotypes and capacities to prime T lympho cytes were analyzed and compared. MC were CD14+, CD1a-, CD33+ and HLA-DR+. Two populations of DC were defined: immature DC were uniformly CD1a-; matur e DC expressed CD1a, CD80, CD86, HLA-DR, CD54 and CD58 but lacked surface C D14. Stimulation of autologous T lymphocytes was studied by measuring their proliferation and cytotoxic function. In more than 80% of our experiments the proliferation of autologous T lymphocytes cocultured with APC pulsed or not with tumor cell lysates was higher than that of T cells cultured alone . DC were more effective than MC in stimulating proliferation of lymphocyte s. The capacity of a patient's autologous bone marrow-derived APC to stimul ate T cells when exposed to autologous tumor cell lysates suggest that such antigen-exposed APC may be useful in specific anti-tumor immunotherapy pro tocols. (C) 2000 Wiley-Liss, Inc.